Drug General Information (ID: DDIENM6AHD)
Drug Name			Linagliptin		Drug Info		Insulin degludec		Drug Info
Drug Type		Small molecule				Hormones
Therapeutic Class		Dpp4 Inhibitors/Antidiabetic Agents				Insulin/Antidiabetic Agents
Structure

Mechanism of Linagliptin-Insulin degludec Interaction (Severity Level: Moderate)
Increased risk of hypoglycemia Click to Show/Hide Mechanism Graph
Drug Name		Linagliptin				Insulin degludec
Mechanism		Hypoglycemic effects				Hypoglycemic effects
Key Mechanism Factor 1
		Factor Name		Hypoglycemia
		Factor Description		Hypoglycemia is a condition in which your blood sugar (glucose) level is below the standard range. It causes irregular or rapid heartbeat, pale skin, numbness of the lips, tongue or cheeks, and sweating.
Mechanism Description		Increased risk of hypoglycemia by the combination of Linagliptin and Insulin degludec

Recommended Action
Management		A lower dosage of the insulin secretagogue or insulin may be required when used in combination with a dipeptidyl peptidase-4 inhibitor.

References
1	Product Information. Onglyza (saxagliptin). Bristol-Myers Squibb, Princeton, NJ.
2	Product Information. Tradjenta (linagliptin). Boehringer Ingelheim, Ridgefield, CT.
3	Product Information. Januvia (sitagliptin). Merck &amp Company Inc, West Point, PA.